Mgr. Adam Svobodník, Ph.D.
Researcher, CZECRIN - Large Research Infrastructure
Correspondence Address:
Palachovo nám. 726/3, 625 00 Brno
E‑mail: |
---|
Total number of publications: 142
2022
-
HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.
Year: 2022, type: Conference abstract
-
Orally Administered Probiotics in the Prevention of Chemotherapy (± Radiotherapy)-Induced Gastrointestinal Toxicity: A Systematic Review With Meta-Analysis of Randomized Trials
INTEGRATIVE CANCER THERAPIES, year: 2022, volume: 21, edition: January-December 2022, DOI
-
Palliative care practice and moral distress during COVID-19 pandemic (PEOpLE-C19 study): a national, cross-sectional study in intensive care units in the Czech Republic
Critical Care, year: 2022, volume: 26, edition: 1, DOI
-
Praxe podávání systémových kortikosteroidů kriticky nemocným pacientům s covidem-19 v České republice – dotazníkový průzkum (studie ASAP-C)
Anesteziologie a intenzivní medicína, year: 2022, volume: 33, edition: 1, DOI
-
Terminologie a praxe paliativní péče na jednotkách intenzivní péče v České republice: výsledky studie PEOpLE‑C19
Anesteziologie a intenzivní medicína, year: 2022, volume: 33, edition: 5, DOI
-
V. národní den klinických hodnocení
Year: 2022, type: Conference
2021
-
Analýzy podskupin v klinických studiích: Na co si dát pozor při interpretaci
Year: 2021, type: Article in Periodical (without peer review)
-
Effect of dexamethasone in patients with ARDS and COVID-19-prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial
TRIALS, year: 2021, volume: 22, edition: 1, DOI
-
Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF).
Year: 2021, type: Conference abstract
-
Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.
Year: 2021, type: Conference abstract